Investigating the Effect of Metformin Combined with Empagliflozin on Glycolipid Metabolism in the Treatment of Type 2 Diabetes Mellitus Com-bined with Obesity Patients
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
目的 评价2型糖尿病(Diabetes Mellitus Type 2,T2DM)合并肥胖患者以二甲双胍联合恩格列净治疗的预后效果,尤其对患者糖脂代谢等方面的影响.方法 选取赤峰市肿瘤医院于2023年3-12月收治的60例T2DM合并肥胖患者作为研究对象,根据入院先后顺序分为两组,各30例.对照组行二甲双胍治疗,观察组联合恩格列净治疗.比较两组患者的治疗效果,比较指标包括体质指数(Body Mass Index,BMI)、血糖水平、脂代谢功能[甘油三酯(Triglyceride,TG)、总胆固醇(Total Cholesterol,TC)、高密度脂蛋白胆固醇(High Den-sity Lipoprotein Cholesterol,HDL-C)]、生活质量评分与不良反应总发生率.结果 观察组的BMI、血糖控制水平、TG、TC、HDL-C水平均优于对照组,差异有统计学意义(P均<0.05);观察组的健康调查简表(MOS Item Short from Health Survey,SF-36)评分优于对照组,差异有统计学意义(P<0.05);两组的不良反应总发生率比较,差异无统计学意义(P>0.05).结论 T2DM合并肥胖患者行二甲双胍联合恩格列净治疗具有安全性与有效性,且促进患者糖脂代谢、体质量控制.
Objective To evaluate the prognostic effect of metformin combined with empagliflozin in patients with type 2 diabetes mellitus type 2(T2DM)and obesity,especially the effect on patients'glucose and lipid metabolism.Methods A total of 60 patients with T2DM and obesity admitted to Chifeng Cancer Hospital from March to December 2023 were selected as the study objects and divided into two groups according to the order of admission,with 30 cases in each group.The control group was treated with metformin,and the observation group was treated with englaglizin.The therapeutic effects of two groups were compared,and comparison measures included body mass index(BMI),blood glucose levels,lipid metabolism[triglyceride(TG),total cholesterol(TC),high density lipoprotein cholesterol(HDL-C)],the scores of quality of life and the total incidence of adverse effects.Results The improvement of BMI,blood glucose control level,TG,TC and HDL-C level in observation group were better than that in control group,and the differences were statistically significant(all P<0.05).The scores of MOS Item Short from Health Survey(SF-36)in observation group were better than that in control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse effects between the two groups(P>0.05).Conclusion T2DM and obese patients with metformin combined with empagliflozin treatment has the safety and effi-cacy,and promote the control of patients'glycolipid metabolism and body mass.
Glycolipid metabolismMetforminEmpagliflozinT2DM with obesityBody mass
NETL
NSTL
万方数据
